Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

The pharma industry registered a 7.5% value growth year-on-year for the month of February, with sales of ₹18,781 crore, ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

Telangana: Natco Pharma has appointed Bhimrao Dattu Jadhav as Senior Vice President - Operations (Formulations) for Pharma ...

Intas Pharma becomes most valuable privately held pharma company A PE deal values Intas at Rs 23,000 crore or USD 3.5 billion, making it the most valued pharma privately held company in India.

Other unlisted companies that have been placed in the top 10 in the report in terms of valuation are Megha Engineering & ...

The National Pharmaceutical Pricing Authority (NPPA) has notified the retail price of 53 new drugs based on applications submitted by individual companies, after finalising the same in the latest ...

Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, ...

The CCI’s first instance of intensified scrutiny was in 2020 which concerned a private equity minority deal in the pharmaceutical sector involving ChrysCapital’s investment* in Intas Pharmaceuticals.

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for the Simponi (golimumab) biosimilar, BAT2506 in the US. Bio-Thera will develop ...